AllianceBernstein
AVIR icon

AllianceBernstein’s Atea Pharmaceuticals AVIR Stock Holding History

AllianceBernstein’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$668K Buy
124,220
+2,900
+2% +$14.4K ﹤0.01% 2568
2026
Q1 		$433K Sell
121,320
-6,500
-5% -$29.9K ﹤0.01% 2707
2025
Q4 		$456K Hold
127,820
– – ﹤0.01% 2699
2025
Q3 		$371K Hold
127,820
– – ﹤0.01% 2842
2025
Q2 		$460K Buy
127,820
+8,600
+7% +$25.6K ﹤0.01% 2690
2025
Q1 		$356K Hold
119,220
– – ﹤0.01% 2693
2024
Q4 		$399K Hold
119,220
– – ﹤0.01% 2737
2024
Q3 		$399K Hold
119,220
– – ﹤0.01% 2774
2024
Q2 		$395K Buy
119,220
+2,800
+2% +$10.4K ﹤0.01% 2797
2024
Q1 		$470K Sell
116,420
-4,310
-4% -$16.9K ﹤0.01% 2605
2023
Q4 		$368K Sell
120,730
-3,890
-3% -$11.8K ﹤0.01% 2756
2023
Q3 		$374K Hold
124,620
– – ﹤0.01% 2721
2023
Q2 		$466K Buy
124,620
+35,120
+39% +$131K ﹤0.01% 2673
2023
Q1 		$300K Buy
89,500
+4,200
+5% +$17K ﹤0.01% 2773
2022
Q4 		$410K Buy
85,300
+5,200
+6% +$26.3K ﹤0.01% 2739
2022
Q3 		$456K Hold
80,100
– – ﹤0.01% 2694
2022
Q2 		$569K Hold
80,100
– – ﹤0.01% 2622
2022
Q1 		$578K Buy
80,100
+200
+0.3% +$1.36K ﹤0.01% 2613
2021
Q4 		$714K Sell
79,900
-16,388
-17% -$255K ﹤0.01% 2593
2021
Q3 		$3.38M Buy
96,288
+6,488
+7% +$180K ﹤0.01% 1834
2021
Q2 		$1.93M Buy
89,800
+70,998
+378% +$2.13M ﹤0.01% 2216
2021
Q1 		$1.16M Buy
18,802
+6,102
+48% +$412K ﹤0.01% 2347
2020
Q4 		$531K Buy
+12,700
New +$409K ﹤0.01% 2559

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AllianceBernstein's AVIR Position: Q2 2026 in Review

AllianceBernstein increased its Atea Pharmaceuticals (AVIR) stake by 2.4% in Q2 2026, buying an estimated $14.4K and bringing the position to 124,220 shares worth $668K. The position accounts for ﹤0.01% of the portfolio, ranked #2568.

AllianceBernstein first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $3.38M in Q3 2021. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • AllianceBernstein held 124,220 shares of Atea Pharmaceuticals worth $668K as of Q2 2026.
  • AllianceBernstein bought 2,900 Atea Pharmaceuticals shares in Q2 2026, an estimated $14.4K.
  • Atea Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2568 holding.
  • AllianceBernstein first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • AllianceBernstein's Atea Pharmaceuticals position peaked at $3.38M in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.